drugset
drugset / Trial / NCT00708084

Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents

NCT00708084 ↗

Phase 2 Completed 48 enrolled Crucell Holland BV
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) in combination with rabies vaccine in healthy children and adolescents.

Timeline

Start
2008-05
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CL184 Monoclonal antibody 20 iu/kg Intramuscular
Comparator human rabies immune globulin Protein / enzyme biologic 20 iu/kg Intramuscular

Indications

rabies